Clinical Protocol and Data Management (CPDM) responsibilities are fulfilled by the USC Norris Clinical Investigations Support Office (CISO). As the centralized clinical trials office for USC Norris, CISO manages, coordinates and provides a full range of services and helps to assure the conduct of high quality cancer clinical research in a safe, compliant and efficient manner. CISO assists investigators in protocol development and facilitates the review to activation process. It is also directly responsible for: 1) hiring, training and supervising clinical research staff, 2) quality assurance; 3) policies and procedures related to clinical trials conduct; 4) support and coordination of clinical research committees (PRMS, DSM, Quality Assurance); 5) metrics and reporting. The Medical Director of CISO is Anthony El-Khoueiry, MD, a highly experienced cancer clinical trialist. He is supported by Assistant Medical Director, Kevin Kelly, MD. CISO's Associate Director, Kay Johnson, RN, announced her retirement in 2014 after more than 20 years of service but continues as a consultant to ensure a smooth transition while a national search is on-going. Day to day activities are handled by two seasoned managers, the Assistant Director for Clinical Research Operations and Assistant Director for Regulatory Affairs. USC Norris has also engaged Huron Consulting to identify strategies for improvement and to help CISO respond to the continued growth and complexity of the clinical research program. CISO has successfully improved efficiency and effectiveness during the project period. Of particular note is USC's decision to implement OnCore enterprise-wide and to revamp the contracting and budgeting processes. Protocol turnaround has declined substantially while the number of IITs has increased. Accrual to interventional therapeutic trials has shown growth despite the increasing complexity of trial eligibility criteria. Other accomplishments include the establishment of a pre-PRMS design and feasibility consultation service, the development of standard operating procedures related to study conduct, the hiring of an education coordinator, and the national certification of research coordinators. In regards to clinical trials participation, USC Norris has continued to build on its successful strategies for the inclusion of minorities using a multi-prong approach. Hispanics and Asian Pacific Islanders represent the two largest minority communities in the USC Norris catchment area. In 2013, Hispanics represented 40.5% of new cancer cases at USC Norris hospitals and 44.8% of accrual to interventional therapeutic trials. Asian/Pacific Islanders represented 14.3% of new cancers at USC Norris hospitals and 11.3% of accrual to interventional therapeutic trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Los Angeles
United States
Zip Code
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244
Park, Sungshim L; Patel, Yesha M; Loo, Lenora W M et al. (2018) Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. Clin Epigenetics 10:110
Liu, Jie; Liang, Gangning; Siegmund, Kimberly D et al. (2018) Data integration by multi-tuning parameter elastic net regression. BMC Bioinformatics 19:369
McDonnell, Kevin J; Chemler, Joseph A; Bartels, Phillip L et al. (2018) A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]2+ cluster. Nat Chem 10:873-880
Schirripa, Marta; Zhang, Wu; Yang, Dongyun et al. (2018) NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 13:e0193640

Showing the most recent 10 out of 842 publications